Innovative Immuno-oncology Focus NewLink Genetics specializes in developing novel immuno-oncology therapies, positioning it as a key player in cancer treatment innovation. Engaging with their R&D efforts could open opportunities in providing specialized biotech services, research tools, or collaborative product development initiatives.

Recent Funding and Growth Potential The company secured a recent $7.5 million Series D funding round, indicating ongoing investment in clinical development. This presents opportunities to offer clinical trial support, investment in infrastructure, or advanced technology solutions to support their expanding pipeline.

Strategic Partnerships and Collaborations Partnerships with industry leaders like Merck and licensing agreements for promising assets such as NLG207 suggest an openness to strategic alliances. Business development efforts might focus on complementing their collaborations with supply chain, manufacturing, or distribution partners.

Recent Restructuring and Funding Challenges Following significant layoffs and restructuring efforts in 2019, there may be a need for operational support, technology upgrades, or consultancy services to streamline internal processes and stabilize growth post-restructuring.